SCHEMBL6315224

SCHEMBL6315224

Cc1ccc(-c2noc(N)c2C(=O)NCc2cccc(Cl)c2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.48
PTGER4 P35408 2/20 0.44
MEN1 O00255 1/20 0.44
HCRTR1 O43613 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
NPC1 O15118 1/20 0.43
MAOB P27338 1/20 0.42
GAA P10253 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317700 0.91 CA1 (0.52) ADORA1PTGER4DYRK1ADYRK1BCA1
SCHEMBL6323513 0.90 ADORA1 (0.47) ADORA1PTGER4MEN1HCRTR1KMT2A
SCHEMBL6318468 0.89 ADORA1 (0.45) ADORA1PTGER4DYRK1ADYRK1BCA1
SCHEMBL6316383 0.88 CHRM4 (0.48) ADORA1KMT2AHPGDMAOBGAA
SCHEMBL6317603 0.87 GAA (0.53) ADORA1MEN1KMT2AMAPTNPC1
SCHEMBL6315582 0.85 CCR1 (0.48) ADORA1PTGER4MEN1KMT2AHPGD
SCHEMBL6318905 0.85 CHRM4 (0.45) KMT2ACA1CA2CA4CA7
SCHEMBL6320945 0.83 KMT2A (0.49) MEN1KMT2AMAPTHPGDCA1
SCHEMBL6318890 0.82 ADORA1 (0.44) ADORA1PTGER4MEN1HCRTR1KMT2A
SCHEMBL6318351 0.82 PTPN22 (0.46) ADORA1MEN1HCRTR1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ADORA1 1592/4885PTGER4 3611/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.